Quick Answer
Citius Pharmaceuticals, Inc. reported Diluted EPS of $3.38 per share (loss) for fiscal year 2025.
Citius Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.38 | +43.4% |
| 2024 | -$5.97 | -7.2% |
| 2023 | -$5.57 | -2321.7% |
| 2022 | -$0.23 | +0.0% |
| 2021 | -$0.23 | — |
| 2013 | $0.00 | — |
| 2012 | $0.00 | — |
| 2011 | $0.00 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.38 | +70.8% | +52.5% |
| June 30, 2025 | -$0.80 | +49.0% | +37.0% |
| March 31, 2025 | -$1.27 | +5.2% | +2.3% |
| December 31, 2024 | -$1.30 | +10.3% | +17.2% |
| June 30, 2024 | -$1.57 | -2516.7% | -17.2% |
| March 31, 2024 | -$1.34 | -1814.3% | +7.6% |
| December 31, 2023 | -$1.45 | -7150.0% | -2316.7% |
| June 30, 2023 | -$0.06 | +0.0% | +14.3% |
- Citius Pharmaceuticals, Inc. showed an increase of +43.4% in Diluted EPS compared to the prior fiscal year.
- The most recent figure is from Citius Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: